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Regulation of type IIα phosphatidylinositol phosphate kinase
localisation by the protein kinase CK2
Katherine A. Hinchliffe*, Antonio Ciruela*, Andrew J. Letcher*, Nullin Divecha†
and Robin F. Irvine*
Inositol lipid synthesis is regulated by several distinct
families of enzymes [1]. Members of one of these
families, the type II phosphatidylinositol phosphate
kinases (PIP kinases), are 4-kinases and are thought to
catalyse a minor route of synthesis of the
multifunctional phosphatidylinositol 4,5-bisphosphate
(PI(4,5)P2) from the inositide PI(5)P [2]. Here, we
demonstrate the partial purification of a protein kinase
that phosphorylates the type IIα PIP kinase at a single
site unique to that isoform — Ser304. This kinase was
identified as protein kinase CK2 (formerly casein
kinase 2). Mutation of Ser304 to aspartate to mimic its
phosphorylation had no effect on PIP kinase activity,
but promoted both redistribution of the green
fluorescent protein (GFP)-tagged enzyme in HeLa cells
from the cytosol to the plasma membrane, and
membrane ruffling. This effect was mimicked by
mutation of Ser304 to alanine, although not to
threonine, suggesting a mechanism involving the
unmasking of a latent membrane localisation sequence
in response to phosphorylation. 
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Results and discussion
Type II PIP kinases from human platelets are phosphoryl-
ated on both serine and threonine residues [3]. To charac-
terise the protein kinases responsible (PIPKKs) more
fully, we set out to purify them from pig platelet lysates.
Separation of lysates on a cellulose-phosphate column
gave two broad peaks of PIPKK activity (Figure 1a).
These were pooled and chromatographed on DEAE-
sephacryl, from which a single peak of activity was eluted
(Figure 1b), and heparin–agarose (Figure 1c), which
resolved two PIPKK peaks. The larger, later-eluting peak
(representing a 4% recovery of the activity present in the
starting material, purified 1638-fold) was retained for
further analysis; attempts at further purification of this
peak resulted in pronounced loss of activity.
The partially purified PIPKK phosphorylated bacterially
expressed recombinant type IIα PIP kinase exclusively on
serine residues (Figure 2a). To identify the phosphoryla-
tion site(s), type IIα PIP kinase was digested with trypsin,
and the peptides eluted from a C-8 HPLC column with a
gradient of increasing concentration of acetonitrile in 0.1%
trifluoroacetic acid (TFA). A single peptide with a molec-
ular weight of ∼6 kDa was identified (data not shown). It
was tentatively identified as residues 286–343 inclusive:
AEQEEVECEENDGEEEGESDGTHPVGTPPDSPG-
NTLSSPPLAPGEFEPNIDVYGIK (using the single-
letter amino-acid code).
Site-directed mutagenesis of the four serine residues in this
sequence was carried out on the full-length protein, and the
ability of the PIPKK to phosphorylate the mutants
assessed. Ser304 (see Supplementary material) was identi-
fied as the sole phosphorylation site: mutation of Ser304 to
alanine (S304A) or aspartate (S304D) completely abolished
phosphorylation (Figure 2b), whereas mutation of all the
other three serines (Ser316, Ser323 and Ser324) to alanine
(S316A,S323A,S324A) did not (Figure 2b). There is no
phosphorylatable amino acid corresponding to Ser304 in the
other type II PIP kinases (β and γ) [4,5], and the residue lies
within the poorly conserved ‘insert’ region of the protein
[6]. In the closely related type IIβ isoform, the central
portion of the insert is disordered and is likely to fold inde-
pendently of the rest of the protein [6]. This raises the pos-
sibility that it participates in isoform-specific functions or
regulation. The presence of putative Src-homology region 3
(SH3)-binding, proline-rich motifs within this region in the
type IIα and β isoforms [4,7,8] supports this idea.
We next attempted to identify the PIPKK activity. The
presence of a 32P-labelled band of ∼40 kDa in the PIPKK
assays (Figure 2b) suggested that the PIPKK co-immuno-
precipitated with type IIα PIP kinase, and underwent
autophosphorylation. The PIPKK was unusual in that it
was able to use GTP as a substrate (Figure 3a), suggesting a
possible identification as protein kinase CK2. This identity
was further supported by its ability to phosphorylate casein
(Figure 3b), by its relative insensitivity to 50 nM stau-
rosporine (data not shown), by its inhibition by the specific
casein kinase inhibitor 5,6-dichloro-1-β-D-ribofuranosyl-
benzimidazole (DRB) (Figure 3c), and by the presence of
CK2 α-subunit immunoreactivity in the PIPKK prepara-
tion (Figure 3d). Confirmation that the partially purified
PIPKK is CK2 came from the ability of recombinant
human CK2 to phosphorylate wild-type type IIα PIP
kinase (incorporating 0.92 pmol phosphate per pmol PIP
kinase) and the S316A,S323A,S324A triple mutant, but not
the S034A or S304D mutants (Figure 3e). Furthermore,
type II PIP kinase immunoreactivity co-immunoprecipi-
tated with CK2 from human platelets (Figure 3f), support-
ing the idea that CK2 phosphorylates PIP kinase in vivo.
The identification of the PIPKK as CK2 was unexpected,
as Ser304 is not contained within a classical CK2 consen-
sus phosphorylation site — three acidic amino acids
immediately carboxy-terminal to the phosphorylation site
[9]. Only one acidic residue is present in this region in
type IIα PIP kinase — Asp305. However, other well
studied CK2 substrates also lack consensus phosphoryla-
tion sites, notably the tumour suppressor protein p53 [10].
CK2 is a constitutively active kinase, although its activity
may be modulated under certain conditions [10,11]. We
previously found that type II PIP kinase immunoprecipi-
tated from unstimulated human platelets was phosphoryl-
ated, predominantly on serine residues [3]. Although
two-dimensional phosphopeptide mapping studies
revealed that even in unstimulated platelets the PIP
kinase was phosphorylated at multiple sites, it is conceiv-
able that CK2 contributes to the observed phosphoryla-
tion in unstimulated cells.
To investigate functional consequences of CK2 phosphoryl-
ation we constructed S304D mutants to mimic phosphoryl-
ation at this site. The mutants did not differ significantly
from wild type in their ability to phosphorylate PI(5)P (data
not shown). However, the transient expression of GFP-
tagged wild-type or GFP-tagged S304D type IIα PIP kinase
in HeLa cells revealed marked differences in subcellular
localisation of PIP kinase on examination by confocal
microscopy. The wild-type enzyme is distributed diffusely
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Figure 2
Identification of the phosphorylation site. (a) Type IIα PIP kinase was
phosphorylated by PIPKK for 20 min with 333 µCi/ml [γ-32P]ATP,
immunoprecipitated as described [12], separated by 10% SDS–PAGE,
transferred to a nylon membrane (Whatman) and the radioactive PIP
kinase band excised. This was hydrolysed in situ by boiling in 6 M HCl
for 3 h and the phosphoamino acids separated according to [14] and
visualised by autoradiography. The positions of unlabelled
phosphoaminoacid standards are indicated. PS, phosphoserine; PT,
phosphothreonine; PY, phosphotyrosine. (b) Site-directed mutagenesis
of type IIα PIP kinase was carried out using a PCR-based method based
on the Quik-change site-directed mutagenesis method (Stratagene).
Bacterially expressed mutant proteins were incubated with [γ-32P]ATP
(133 µCi/ml) and PIPKK for 10 min, then immunoprecipitated, separated
by SDS–PAGE, transferred to nitrocellulose, autoradiographed to
visualise 32P-labelling (upper panel; arrow indicates type IIα PIP kinase),
and probed for type II PIP kinase immunoreactivity (lower panel) to
demonstrate comparable loading. W, wild type; A, S304A mutant; D,
S304D mutant; T, S316A,S323A,S324A triple mutant. Molecular
weights (in kDa) are indicated.
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Figure 1
Partial purification of PIPKK activities.
(a) Platelets from 4 l pig blood were stimulated
with bovine thrombin (0.2 units/ml) for 1 min at
37°C and lysed with 1% Triton X-100 as
described [12]. Lysates were clarified by
centrifugation at 100,000 × g for 30 min at 4°C
and applied to a 30 ml cellulose-phosphate
column (Whatman) as described [13].
Fractions (4 ml) eluted with the indicated
gradient of NaCl concentration (dashed line)
were collected, and 10 µl aliquots assayed for
PIPKK activity (solid circles) using recombinant
type IIα PIP kinase as a substrate. (b) Active
fractions from (a) were pooled, diluted threefold
and chromatographed on a DEAE-sephacryl
column eluted with increasing NaCl
concentration. (c) The pooled active fractions
from (b) were applied to a phenylsepharose
column but failed to stick (data not shown). The
flow-through was diluted 10-fold, applied to a
5 ml heparin–agarose column (Pharmacia) and
eluted with increasing NaCl concentration
(dashed line). The dotted line in (a,b) indicates
the protein content of the fractions.
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throughout the cytoplasm, being largely excluded from
the nucleus (Figure 4a). In contrast, the S304D mutant
co-localises with the cortical actin network at or near the
plasma membrane (Figure 4b). Preliminary results show
that the cortical distribution of the S304D mutant is
resistant to detergent treatment (data not shown), consis-
tent with the formation of a complex between the PIP
kinase and a protein structure, perhaps a component of
the cytoskeleton.
The morphology of cells expressing the S304D mutant is
different from that of cells expressing the wild-type PIP
kinase. Actin-rich membrane ruffles are present in the
S304D-transfected cells (Figure 4b), whereas such struc-
tures are not found in the cells transfected with wild-type
kinase (Figure 4a). This phenomenon is highly repro-
ducible, and might suggest a role for type IIα PIP kinase
in modulation of the cytoskeleton. Further work will be
needed, however, to determine whether this ruffling is
really due to the positioning of the PIP kinase close to the
plasma membrane.
These findings suggest that Ser304 phosphorylation gen-
erates a membrane (or juxtamembrane) localisation motif
on the protein. This is not simply due to the presence of a
negative charge at position 304, as the S304A mutant also
localises to the plasma membrane (Figure 4c), where it
also appears to promote membrane ruffling. However,
replacement of Ser304 with threonine has no effect on
distribution; GFP-tagged S304T type IIα PIP kinase has
a distribution identical to that of the wild-type enzyme
(Figure 4d). This could suggest that the presence of a
free hydroxyl group on amino acid 304 allows the protein
to adopt a conformation in which a plasma membrane tar-
geting sequence is masked. Phosphorylation of this
residue (or its experimental substitution with an amino
acid lacking a free hydroxyl group), would then cause
unmasking of the putative membrane localisation
sequence and consequent translocation of the PIP kinase
to the plasma membrane.
We tested an alternative possibility, that phosphorylation
of type IIα PIP kinase at Ser304 generates the binding
site for an interacting protein which then sequesters the
PIP kinase within the cytoplasm, by incubating HeLa
cells transfected with GFP-tagged wild-type type IIα PIP
kinase with 30 µM DRB and looking for changes in sub-
cellular localisation of the enzyme. None were observed
after 2, 6 or 24 hours treatment (data not shown), despite
the fact that the inhibitor had abolished casein kinase
activity in cell lysates.
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Figure 3
Identification of the PIPKK as CK2. (a) Type IIα PIP kinase was
incubated with PIPKK and GTP (75 µM; 667 µCi/ml [γ-32P]GTP) for
30 min, immunoprecipitated and separated as above, and
autoradiographed. The arrow indicates phosphorylated type IIα PIP
kinase. (b) Casein (0.5 µg; Sigma) was incubated with PIPKK and
[γ-32P]ATP (100 µCi/ml) for 30 min, resolved by SDS–PAGE on a
15% gel, transferred to nitrocellulose and visualised by
autoradiography. The arrow indicates phosphorylated casein.
(c) PIPKK phosphorylation of type IIα PIP kinase was carried out for
10 min with [γ-32P]ATP (100 µCi/ml) in the presence or absence of the
indicated concentrations of DRB (Alexis). The arrow indicates type IIα
PIP kinase. (d) Western blot of PIPKK resolved on a 10% gel with an
anti-CK2 alpha subunit antibody (UBI) developed using peroxidase-
linked anti-rabbit antibodies (Amersham). The lane marked + contains
a positive control (A431 cell lysate). CK2α is indicated by the arrow.
(e) Top panel, autoradiograph showing phosphorylation of wild-type
type IIα PIP kinase (W) and the S316A,S323A,S324A mutant (T) but
not of the S304A (A) or S304D (D) mutants by recombinant human
CK2 (10 units for 30 min in the presence of 133 µCi/ml [γ-32P]ATP).
The arrow indicates the position of type IIα PIP kinase. The
autoradiographed blot was subsequently probed with antibodies
against type II PIP kinase to demonstrate its presence in all lanes
(lower panel). (f) CK2 was immunoprecipitated from human platelet
lysate with an anti-CK2 polyclonal antibody (Calbiochem) coupled to
protein G–sepharose (Pharmacia). Immunoprecipitates were resolved
by 10% SDS–PAGE, transferred to nitrocellulose, and the blot probed
with antibodies against type II PIP kinase. Anti-PIP kinase
immunoreactivity was present in duplicate immunoprecipitates, but
absent from controls in which either the immunoprecipitating antibody
or the platelets were omitted (data not shown). 
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PI(5)P is likely to be the main physiological substrate of the
type II PIP kinases [2], but because of its relative novelty
nothing is currently known about its route of synthesis
within the cell, and whether it possesses a signalling or regu-
latory function in its own right or is merely a precursor for
PI(4,5)P2 synthesis via type II PIP kinase action [1]. It
seems likely that phosphorylation of Ser304 controls the
accessibility of a putative pool of PI(5)P in the plasma mem-
brane to type IIα PIP kinase. Alternatively, given the ability
of the type II PIP kinases to use PI(3)P [2], it is also possible
that regulated association of type IIα PIP kinase with the
plasma membrane may increase production of the signalling
lipids PI(3,4)P2 and PI(3,4,5)P3. Whether the observed
induction of membrane ruffles in cells transfected with the
S304A and S304D mutants reflects a physiological role for
type IIα PIP kinase in this process, and whether it results
from removal of PI(5)P or from production of PI(4,5)P2,
PI(3,4)P2 or PI(3,4,5)P3, remains to be determined. 
Supplementary material
Additional methodological detail is available at http://current-
biology.com/supmat/supmatin.htm.
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Figure 4
Subcellular localisation of GFP-tagged type IIα PIP kinase mutants.
(a) Wild-type type IIα PIP kinase, (b) the S304D mutant, (c) the
S304A mutant or (d) the S304T mutant were expressed as GFP
fusion proteins in HeLa cells. After 24 h cells were fixed, stained for
actin and examined by confocal microscopy. The images obtained in
the green channel (GFP–PIP kinase), in the red channel (actin) and by
superimposing the two (overlay; yellow demonstrates co-localisation of
actin and GFP–PIP kinase) are shown.
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Supplementary materials and methods
Recombinant PIP kinase production
Recombinant human type IIα PIP kinase and its mutants used in these
experiments were expressed in Escherichia coli as GST fusion pro-
teins, purified on glutathione sepharose 4B (Pharmacia) and the GST
moiety removed by thrombin digestion.
PIPKK assays
Column fractions were rapidly screened for PIPKK activity by incubation
at 30°C in 96-well plates precoated with type IIα PIP kinase, in the pres-
ence of [γ-32P]ATP (5 µM, 100 µCi/ml) dissolved in kinase buffer (80 mM
KCl, 10 mM magnesium acetate, 2 mM EGTA, 50 mM Tris pH 7.4), and
Cerenkov counting of individual wells after thorough washing. Radiola-
belled proteins were subsequently removed from the wells with
SDS–PAGE sample buffer and resolved by SDS–PAGE to ensure that
detected radiolabelling was due to PIP kinase phosphorylation.
Except where indicated, PIP kinase phosphorylations for phospho-
amino acid analysis, determination of phosphorylation site and PIPKK
identification were carried out in a volume of 15–20 µl by mixing
PIPKK, substrate (type IIα PIP kinase or casein) and ATP (5 µM final
concentration dissolved in kinase buffer, to which the indicated amount
of [γ-32P]ATP had been added). All phosphorylation experiments were
carried out at 30°C. In all cases, PIP kinases were immunoprecipitated
from the reaction mixture after the addition of 0.5–1 ml ice-cold
immunoprecipitation buffer (50 mM Tris pH 7.5, 140 mM NaCl, 0.1%
Triton X-100, 5 mg/ml bovine serum albumin) using the antibody
MAC334 [S1] which had previously been covalently coupled to protein
G–sepharose 4B beads (Pharmacia) with dimethylpimelimidate
(Pearce). Washed immunoprecipitates were resolved by SDS–PAGE
on 10% gels, electrophoretically transferred to blotting membranes,
autoradiographed using blue X-ray film (Kodak) and, where indicated,
probed with anti-type II PIP kinase antibodies and horseradish peroxi-
dase-linked anti-rat light chain second antibodies (Sigma) as described
[S2]. All immunoblots were developed using the enhanced chemilumi-
nescence method (Amersham). 
Localisation of PIP kinase mutants
Amino-terminally tagged GFP fusion proteins were produced by ligat-
ing type IIα PIP kinase sequences into the pEGFP-C1 vector (Clon-
tech). Plasmids were introduced by calcium phosphate transfection
[S3] into HeLa cells grown on coverslips. After 24 h, cells were fixed in
4% paraformaldehyde, permeabilised with 0.1% Triton X-100, stained
for actin with Texas Red phalloidin (5 µg/ml) (Molecular Probes), and
mounted in Vectashield (Vector Laboratories Inc.). Slides were exam-
ined by confocal microscopy.
Ser304
Due to a sequencing error, one original sequence of type IIα PIP kinase
lacks Ser304 [S4].
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